Login to Your Account



Clinic Roundup


Thursday, April 26, 2012

• Cytokinetics Inc., of South San Francisco, reported results from two Phase II studies of CK-2017357 in amyotrophic lateral sclerosis (ALS), showing that the drug was safe and well tolerated when dosed with Rilutek (riluzole, Sanofi SA), the only approved treatment for ALS. Data were presented at the Academy of Neurology meeting in New Orleans.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription